Ross R. Atherosclerosis - An inflammatory disease. N Engl J Med 1999;340: 115-126. doi: 10.1056/nejm19-9901143400207
Lbby P. Inflammation in atherosclerosis No longer a th- eory. Clin Chem 2021; 67:131-142.doi:10.1093/clinchem-m/hvaa275
Chaldakov GN. Antitubulins - a new therapeutic ap-proach for atherosclerosis? Atherosclerosis 1982;44: 385-390. doi: 10.1016/0021-9150(82)90013-2
Chaldakov GN. Anti-inflammatory drugs and is-chemic heart disease: New considerations (A cell biologist's proposal to cardiologists). J Am Coll Cardiol 1991; 17(6):1445-1447.
Chaldakov GN. Proposal for clinical trials using anti-in-flammatory drugs in the therapy of angina pectoris, myocardial infarction and coronary restenosis after angioplasty and bypass grafting. Med Hy-potheses 1992;37(2):74-75. doi:10.1016/0306-9877(92)90043-c
Chaldakov GN, Nikolov SD. Ultrastructure of the arterial smooth muscle cell. In: Wolf S, Werthessen NT, editors. The Smooth Muscle of the Artery. New York City, NY: Plenum Press. Adv Exp Med Biol 1975; 57:14-20.
. Chaldakov GN, Nikolov S, Vancov V. Fine morphological aspects of the secretory process in arterial smooth muscle cells. II. Role of microtubules. Acta Morphol Acad Sci Hung 1977;25: 167-174.
Ghenev PI, Aloe L, Kisheva AR, Singh M, Panayotov P, Fiore M, et al. QUO VADIS, ATHEROGENESIS? Part 1. Smooth muscle cell secretion – how foe be-comes friend in the fight against the atherosclerotic plaque. Biomed Rev 2017;28:134-138.
Chaldakov GN, Zhelyazkova-Savova MD, Panayotova D, Fiore M, Yanev S. Phenotypic modulation of smooth muscle cells and matrix metalloproteinases as targets for atherosclerotic plaque stabilization. Biomed Rev 2020;31:
- 60. doi: 10.14748/bmr.v31.7704
Chaldakov GN, Ghenev PI. Colchicine, inflammation and fibrosis in cardiovascular disease: Merging three classical tales. Biomed Rev 2017; 28: 110-115. doi: 10.14748/bmr.v28.4
Chaldakov GN. Colchicine, a microtubule-disassembling drug, in the therapy of cardiovascular diseases. Cell Biol Int 2018;42(8):1079-1084.doi:10.1002/cbin.10988
Yanev S, Fiore M, Hinev A, Ghenev PI, Hristova MG, Panayotov P, et al. From antitubulins to trackins. Biomed Rev 2016;27:59-67.
Chaldakov GN, Aloe L, Kádár A, Ghenev P, Fiore M, Pancheva RZ, et al. Homage to George E. Palade. Cell protein secretion in vascular biology: overview and updates. ABMJ 2021; 4(1): 31-43. doi: 10.2478/abmj-2021-0004
Cecconi A, Vilchez-Tschischke JP, Mateo J, Sanchez Gonzalez J, España S, et al. Effects of colchicine on atherosclerotic plaque stabilization: a multimodality imaging study in an animal model. J Cardiovasc Transl Res 2021;14(1):150-
doi:10.1007/s12265-020-09974-7
Lee JZ, Singh N, Howe CL, Low S-W, Huang JJ, Ortega G, et al. Colchicine for prevention of post-operative atrial fibrillation. A meta-analysis. J Am Coll Cardiol Clin Electrophyisol 2016;2(1):78-85. doi:10.1016/j. jacep.2015.09.016
Nidorf M, Thompson PL. Effect of colchicine (0.5 mg twice daily) on high-sensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease. Am J Cardiol 2007; 99(6):805-7. doi:10.1016/ j.amjcard.2006.10.039.
Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention o f cardiovascular disease. J Am Coll Cardiol 2013, 61:404-410
Imazio M, Nidorf M. Colchicine and the heart. Eur Heart J 2021; 1–16 doi:10.1093/eurheartj/ehab221
Robertson S, Martinez GJ, Payet CA, Barraclough JY, Celermajer DS, Bursill C. Colchicine therapy in acute coronary syndrome patients acts on caspase-1 to suppress NLRP3 inflammasome monocyte activation. Clin Sci (Lond) 2016; 130:1237-1246. doi: 10.1042/ CS20160090
Martinez GJ, Robertson S, Barraclough J, Xia Q, Mallat Z, Bursill C. Colchicine acutely suppresses local cardiac production of inflammatory cytokines in patients with an acute coronary syndrome. J Am Heart Assoc 2015;4:e002128. doi: 10.1161/ JAHA.115.002128
Tardif J-C, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, et al. Efficacy and safety of lowdose colchicine after myocardial infarction. N Engl J Med 2019;381(26):2497-2505. doi: 10.1056/NEJMoa1912388
Vaidya K, Arnott C, Martínez GJ, Ng B, McCormack S, Sullivan DR, Colchicine therapy and plaque stabilization in patients with acute coronary syndrome. J Am Coll Cardiol Img 2017; doi: https://doi.org/ 10.1016/j.j-cmg.2017.08.013
Seung-Yul ee, Young-Hoon Jeong, Kyeong Ho Yun, et al. P2Y12 Inhibitor monotherapy combined with colchicine following PCI in ACS patients. Cardiovsc Intv 2023;16(15):1845-1855.doi:10.1016/j.jcin.2023.05.03
Costa F, Micari A. Aspirin-free strategy after ACS implementing colchicine: looking for a substitution? J Am Coll Cardiol Intv 2023;16 (15) 1856–1859.
Zile MR, Koide M, Hiroshi Sato H, Cooper IV G. Role of microtubules in the contractile dysfunction of hypertrophied myocardium. J Am Coll Cardiol 1999; 33(1): 250-260.
Abrantes AM, Nogueira-Garcia B, Alves M, Teixeira Passos D, Brito D, et al . Low Dose Colchicine in Coronary Artery Disease - Systematic Review and MetaAnalysis. Circ Rep 2021;3(8):457-64.
Imazio M, Andreis A, Brucato A, Adler Y, De Ferrari GM. Colchicine for acute and chronic coronary syndrome s2.0 H20e;a1r0t 6(20):1555-60.
Andreis A, Imazio M, De Ferrari GM. Colchicine for the treatment of cardiovascular diseases:old drug, new targets. J Cardiovasc Med 2021;22(1):1-8.
Schattner A. Colchicine - new horizons for an ancient drug. Review based on the highest hierarchy of evidence. Eur J Intern Med 2022;96:34-41.
Mullen M, Jin XY, Child A, Stuart AG, Dodd M, Aragon-Martin JA. Irbesartan in Marfan syndrome (AIMS): a double-blind, placebo-controlled randomised trial. Lancet 2019;394:2263–2270.doi:10.1016/S0140 6736(19)32518-8
Email this article (Login required) 
